Shansong Zheng
Jinan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Translational Model-Informed Dose Selection for Iruplinalkib, a Selective Oral ALK/ROS1 Tyrosine Kinase Inhibitor.
Journal: Clinical and translational science
Published: February 12, 2025
Pharmacokinetic/pharma-codynamic study of pralurbactam (FL058) combined with meropenem in a neutropenic murine thigh infection model.
Journal: Frontiers in microbiology
Published: October 25, 2024
FL058, a novel β-lactamase inhibitor, increases the anti-Mycobacterium abscessus activity of imipenem.
Journal: International journal of antimicrobial agents
Published: August 09, 2024
Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors.
Journal: Clinical and translational science
Published: July 18, 2024
Pharmacokinetics, metabolism, excretion and safety of iruplinalkib (WX-0593), a novel ALK inhibitor, in healthy subjects: a phase I human radiolabeled mass balance study.
Journal: Expert opinion on investigational drugs
Published: January 15, 2024
First-in-human study to evaluate the safety, tolerability, and population pharmacokinetic/pharmacodynamic target attainment analysis of FL058 alone and in combination with meropenem in healthy subjects.
Journal: Antimicrobial agents and chemotherapy
Published: December 06, 2023
In vitro pharmacokinetics/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales.
Journal: Frontiers in pharmacology
Published: August 24, 2023
Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.
Journal: Investigational new drugs
Published: November 03, 2022
WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple EGFR mutations.
Journal: Annals of translational medicine
Published: May 10, 2022
Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations.
Journal: Bioorganic & medicinal chemistry letters
Published: February 22, 2022
Design, Synthesis, and Evaluation of Tetrahydropyrrolo[1,2-c]pyrimidines as Capsid Assembly Inhibitors for HBV Treatment.
Journal: ACS medicinal chemistry letters
Published: July 18, 2017
Showing 1-11 of 11
Last Updated: 09/26/2026